{"name":"Verve Therapeutics, Inc.","slug":"verve","ticker":"VERV","exchange":"NASDAQ","domain":"vervetx.com","description":"Verve Therapeutics, Inc. (VERV) is a biotech company focused on gene editing therapies. The company is developing a pipeline of treatments for cardiovascular diseases. Verve's lead product, VERVE-101, is a monoclonal antibody targeting PCSK9 for the treatment of high cholesterol. The company is positioned to disrupt the cardiovascular disease treatment market with its innovative gene editing approach.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Sekar Kathiresan","sector":"Biotech — Gene Editing","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":8000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Verve Therapeutics Announces FDA Fast Track Designation for VERVE-101","summary":"Verve Therapeutics announced that the FDA has granted Fast Track designation to VERVE-101 for the treatment of patients with high cholesterol.","drugName":"VERVE-101","sentiment":"positive"},{"date":"2022-12-14","type":"earnings","headline":"Verve Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Verve Therapeutics reported its third-quarter 2022 financial results, highlighting progress in its pipeline and cash position.","drugName":"","sentiment":"neutral"},{"date":"2022-09-06","type":"deal","headline":"Verve Therapeutics Announces Collaboration with AstraZeneca to Develop Gene Editing Therapies","summary":"Verve Therapeutics announced a collaboration with AstraZeneca to develop gene editing therapies for cardiovascular diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQNFl3d0lNMXk2bnJXRHVfZXdaTWJVczZMVXYzb3BQRTdIZFN2aUlMMmpfdGhyekg3bmt4ZC1sWHYxOVZQeHZyeEl1YU9lMnBfUFVRckhXeUIwVFVPb0VmS3FLR0VzT0pQNXhYaGplM21PbXJvV2ljSml4NWdiY2dQd1dwcE1tVGhsR3NzemJKOFNxSkJsbVhzQw?oc=5","date":"2025-07-21","type":"pipeline","source":"MarketBeat","summary":"3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat","headline":"3 Bullish Biotech Stocks With Explosive Growth Trends","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOaDl3V3NtVUxybDNYSjQzSWs2QXE0VkhHQjNlN3pjbVdsdm9ldzF6bXFxZXI5bEt6SnlsQ0lPT2VsdDdTeDlwRUJSWXVzeFBYTjVKaFAzeHpoWFRqRlZlZld4dGNqS01pM1RJR0VGNmo4cUtmUTlqYzZTRTE4elE3VUtQWGw?oc=5","date":"2025-07-10","type":"pipeline","source":"Yahoo Finance","summary":"Verve Therapeutics, Inc. (VERV): A Bull Case Theory - Yahoo Finance","headline":"Verve Therapeutics, Inc. (VERV): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNQjdqOEFueU9Zd3oxMXRaUHp0NEtkTEM4U0dHTFJQa21oMW9nM2g2N3NFOS04WU5ZNklkYmdPT2k0cnh0MEN6UjlmV3BYcWt5ZjFVQjUwOXpfY2hIbG9PNm9UbjVsX1dWU3prYV8wSGhEQUlDLUF3YzVuUGlJRk10bmZCVjA1U29LSWdLQkFFLUdWTEJPMGpQSg?oc=5","date":"2025-06-20","type":"pipeline","source":"The Motley Fool","summary":"Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - The Motley Fool","headline":"Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWG5nR1hNQTYzVmo1bzZDUzM0LWRqeUZDeTUzVUNGdFE1cmxHOU81bHluNVZ1QTJmcnprSmFmV1ZVU091b3hLQnlQS2xjVm15YU1mamJpbDNwNlpfckpGN0dISTRGQVVfQzhpMTFEUXl2Q0xOSU5tOXREODZ2ZHprWHdFRFhRQ244Z2JhenpQZ05OUVFuMnE0ejNCRTBWengtX1VsaWk1TDFVcUhSdDVJZ2lXYk1nZi1OS3Vjb3diZw?oc=5","date":"2025-06-17","type":"deal","source":"Eli Lilly","summary":"Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - Eli Lilly","headline":"Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOUDdrUFhJdXlLSjRaVFlFM0pMLUYxZ3ZmV3RkYUhZaXRLeFpmd3ZTVlN3eElodnNiM3pKcEg0cDI0ejZmNmxVVklVcUhiTElPbG1rTzJzX0g3Q2pyOXRKVTRqNHh5SWJoQURTWFFnNFBMell0TkxIYU9EalpSX0kyQ2JKWHNrSHZnYTl4ZktqbGFjVFJyWW04dlYzWFEtWXZENDF1bjVYdDNhVXNXOWQwOG1SMDVoRHZtbHpxRXVjbXZCTU5mYlUtMzJhcm5fTk9HbWNWbGJJbjg0LTBqRUdB?oc=5","date":"2025-06-17","type":"deal","source":"Reuters","summary":"Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters","headline":"Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeHVtTVQ4Yk5ONDVQOG5fdWJTNG1PR2I0MlU4a1ZoMloyZjRIWk5QY21la1NHZ3VHck16b1dYNU0zblc5ajF6OGVjRmM2dzB1cWtxMHZBeDdUUUNNSHlMQk1EMk9xTm4xNkVKTUZ5cVcxN2x2MWM2cFhRTVhfWGRWQ2tteU1Ub3dSeUhUcGQzdG8ydlptblJ6dlhXcXdBa0JNRDdxUlRpNzAwYnZiaU5mVnNvckFSOGRM?oc=5","date":"2025-06-17","type":"deal","source":"Seeking Alpha","summary":"Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol (NYSE:LLY) - Seeking Alpha","headline":"Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol (NYSE:LLY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQNUJFOV90WjJ5OFlTUHBINHNfcS1ZZlNzN2hkX0xWUFdEUzZQUkpZVmZjUXdRVlJtbFgzTk5QSjlVaEFNdldCdjluMW5oRXhqRXNKRHZENHhfOExvU0laQjhyeGhNR0JyQk00M0ZQVHB3ckVxcHpLSDJUYl9vMlJjRWpaejBRZw?oc=5","date":"2025-06-17","type":"deal","source":"Yahoo Finance","summary":"Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - Yahoo Finance","headline":"Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQSGF2U2xHbE1zRDd0RWJGeEdBZkt3MjVMc0FaY3pIZDFOYzVYWWxWOWJKYTlycnNaRGJST1E5dWtETEttQUF2TTFNNHNFTG5zb24tSElEVXZhVzBhaVFObmRVZklRRG80bktYNld0ZzlBc1Uxckc3SEktRlZ3YTRQZU04WnZUMm5PTWxIemx3MjZFeWh5RTc5TTlack03UUhjQ2kzSzJROHJvTVlyVW9uMUtzNllrdXh6YXRNTQ?oc=5","date":"2025-06-17","type":"pipeline","source":"Seeking Alpha","summary":"Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha","headline":"Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOa0dXZDVoVFpWbmxyQ214RVU3blJXb3RBcWpUUFZZYVBFamlNb21OUWdGR2hQUkNFTzFFT2RKT3diYXBuaEZweDBpWnRLd25BTzZ3Rm5US3BrXzlSbVJudTVweHoxZTVQMXNmdUU4U3E5V1dULTNVU25rOUowSFAwWU14TGFvcHF6b3lBeTNheVZRYVlLSEZDV1dtS1NNWHpjTFBUNXhDSQ?oc=5","date":"2025-06-17","type":"pipeline","source":"Investor's Business Daily","summary":"Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily","headline":"Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNb3VFQzlLMTBHWkxIcWZmcWluSWh1T1gzWU8xa0tYdlQtOXBlcUdsTXlpSlBsSWtJdDJYWGVxZzNvVzBIdkwtTENXeWlyY2lCbDVzajM1LUFVWTYxNnlfQ2t0cmttVHFuUW1zNFVjQjBQZ1VNRVctMUMtb25iMTJEOTBjdjh5S00?oc=5","date":"2025-06-17","type":"pipeline","source":"Barron's","summary":"Verve Therapeutics Stock Soars 77% After Eli Lilly’s $1.3 Billion Bid - Barron's","headline":"Verve Therapeutics Stock Soars 77% After Eli Lilly’s $1.3 Billion Bid - Barron's","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-28","type":"pipeline","source":"simplywall.st","summary":"Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st","headline":"Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE14aEo1LTFJaWRkV3IwQ2o4S2IySm93Zm1jVFlHS0o1MTN5VXBtTENaTUktRGZ3M25tYm42eUsyOU9wcEJZWW5COTdJNTk0OEJOT09n?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"Verve Therapeutics Stock Price, News & Analysis - Stock Titan","headline":"Verve Therapeutics Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Amgen","Pfizer"],"therapeuticFocus":["Cardiovascular Disease","Gene Editing"],"financials":null,"yahoo":null}